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Retinoids and Cancer 
The synt hetic retinoids represent a new class of drugs wh ich 
a re highly effective in t he treatment of a broad spectrum of 
dermatologic d isease, including cystic acne, psori asis, and cu-
taneous di sorders of keratinization [1 - 3]. Moreover, t he use of 
synthetic retinoids in cancer prevent ion and therapy fo r both 
cutaneous and in te rna l t umors is potent ially the most signi fi-
cant clinica l use of t hese dru gs. 
Vitamin A de!iciency may provide a conceptua l link in un -
derstanding how retinoids may be effective as t herapy fo r 
benign dermatoses and be of value in t he treatment and pre-
vention of skin ca ncer. One characteristic feature of vi ta min A 
defi ciency is a squamous metaplasia of a variety of epit helia, 
including t he t rachea, cornea, urina ry bladder, pa rotid gland , 
p rostate, and ute rine cervix l4) . Increased cell proli fe ration and 
hyperkeratosis a re features of both squamous metaplas ia and 
some benign dermatoses, for example, psoriasis. S imilarly, fo l-
licular hyperkeratosis is seen both in vita min A defi ciency and 
in acne, keratosis follicul aris and pityriasis rubra pila ris. 
The findin g t hat retinoids rapidly reverse t he squamous 
metaplasias induced by both vi tamin A deficiency and by 
carcinogens supports t he concept t hat retinoids may be of va lue 
in cancer chemoprophylax is. Furt hermore, vitamin A defi -
ciency may be a precancerous disease. For example, vitamin A 
deficiency in t he rat enhances t he susceptibility of t he respi -
ratory t ract, bladder, and colon to experimenta l carcinogenesis. 
I n humans, epidemiologic studies have assoc iated t he incidence 
of cancer with decreased se rum retinol [5]. 
During t he past 10 years, in practical demonstration of t he 
above concept, several retinoids have been used in a nimals and 
h umans in t he treatment or prevent ion of skin tumors. Ini t ia lly, 
tretinoin (all -trans- retinoic ac id) was used both topically and 
systemically. More recent ly, isotretinoin (13-cis- retinoic acid) 
a nd aromatic derivat ives of retinoic acid (etretinate) and reti-
n oidal benzoic acid derivatives (arotinoids) have been demon-
strated to be more effective and less tox ic t han t retinoin in t he 
t reatment of skin diseases, including tumors [1 - 3,6]. 
Moon and I t ri suggest t hat t here a re several a reas where 
r etinoids may prove useful in clinical oncology: (1) for t reat-
ment of advanced disease, (2) for t reatment which is adjuvant 
to other ant icancer therapy, (3) for reversal or different iation 
of preneoplastic les ions, (4 ) for prevent ion of cancer in high-
r isk populations, and (5) for t he prevent ion of cancer in t he 
general population [7]. 
The synthetic retinoids, isotretinoin and etretinate, have 
been used in t he t reatment and prevent ion of cutaneous malig-
nancy in patients wi t h mul t iple basal cell carcinomas due to 
chronic sunlight exposure, t he nevoid basal cell carcinoma 
syndrome, or xeroderma pigmentosum; mult iple actin ic kera-
toses; mul t iple keratoacanthomas (Ferguson-Smit h); so litary 
la rge keratoacanthomas; porokeratosis of Mibelli wi t h malig-
nant degeneration (squamous cell carcinoma, Bowen's disease); 
malignant eccrine poroma; epidermodysplasia verruciformis; 
o ral leukopla ki a; cutaneous metastases of malignant melanoma 
a nd cutaneous T -celllymphoma (mycosis fun goides and Sezary 
syndrome) [ 1,2,6]. Aside from t he actinic keratoses, t he soli tary 
keratoacanthomas, and approximately 10% of basa l ce ll carci-
nomas, t he synt hetic retinoids usually do not cure cutaneous 
tumors but do produce va riable degrees of part ia l regression 
when give n at high dosage. 
P recancerous diseases in organs other t han t he skin also 
h ave been reported to respond to retinoids. T wo placebo-con-
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t rolled, double-blind clinical t rials in E urope have demonstra-
ted t hat etretinate, at 25 mg/day for 2 yea rs, is effective in t he 
prevent ion of new superfic ial urina ry bladde r t umors [8,9]. 
Some patients had complete prevent ion of new tumors, wh ile 
others had part ia l prevent ion with a reduction in incide nce of 
new lesions. The beneficia l effects of t he retinoid were not 
significant ly different from placebo unt il t he twelft h mont h of 
these studies, indicating t he need fo r p rolonged periods of 
obse rvation in chemoprevention tr ia ls. In cont rast, a mul t icen-
ter American study using isotretinoin for 6 months (0.5 mg/ 
kg/day) fa iled to demonstrate a chemoprevent ive effect in 
patien ts wi t h bladder tumors when compared with historic 
cont rols [10]. T esting of retinoids in breast and lung cancer is 
an t icipated. 
Severa l lessons can be extracted from the experience ob-
tained to date in t he study of cancer chemoprevent ion wit h 
retinoids t hat can be helpful in t he design of new trials. For 
example, in order to fac ili tate t he determination of a chemo-
prevent ive effect in patients wi t h mult iple basal cell carcino-
mas, it is best to choose patients wit h a high pretreatment 
yearly incidence of tumors, since it is known t hat t he risk of 
developing a new basal cell carcinoma is d irectly related to t he 
number of prev ious tumors. However, s ince patients wit h t he 
nevoid basal cell carcinoma syndrome and xeroderma pigmen -
tosum, fo r example, may have numerous punctate t umors, it 
becomes necessary to biopsy and t reat each existing lesion prior 
to including such patients in chemoprevent ion t rials for two 
reasons. First, it is necessary to establish an accurate pretreat-
ment incidence rate which can be used for compar ison with 
subsequent t reatment data. Second, t he elimination of a ll 
ex isting punctate lesions greatly facili tates t he detection of new 
lesions. 
Pilot studies of new cancer chemopreventive agents are best 
done wit h a subset of patients at highest risk. The dose em-
ployed in ini t ial studies should be sufficient ly high to ensure 
t hat chemoprevent ive activity, if present, will be obse rved 
wi t hin a reasonable period of t ime, and yet not so high as to 
interfere with patient compliance due to toxicity. If efficacy is 
seen in pilot studies, then in subsequent large-scale cl inical 
t rials lower doses should be employed in order to minimize or 
avoid acute and chronic toxicit ies, s ince t he need for chronic, 
if not lifet ime, maintenance t herapy for cancer chemopreven -
tion has been demonstrated in many reports . 
Concerning t he mechani sm of action of retinoids at t he 
cellular and molecul ar levels, t here is no single hypothesis t hat 
can encompass t he diversity of observed effects. As a genera li -
zation, retinoids probably modi fy cell proli fe ration and diffe r-
ent iation by altering gene expression afte r being t ransported to 
the nucleus by specific cytoplasmic binding prote ins in a ma n-
ner somewhat analogous to steroid hormone action. Examples 
of some retinoid effects at the cellu lar and molecular levels 
include labilization of cellula r membranes at toxic doses, stim -
ulat ion of gap junctions wit h enhanced ce llular communication, 
stimulation of immune responses such as interleukin 2 produc-
tion by T helper cells with resul ta nt T killer cell proliferation 
(ll], antagonism of polypept ide growt h facto rs such as prolac-
tin, stimulation of glycoprotein synthesis, inhibi t ion of pros-
taglandin production and antagonism of certai n prostaglandin 
effects by some retinoids such as 4-hydroxyphenylretinamide, 
and inhibi t ion of collagenase production. Roberts and Sporn 
have suggested t hat it may be appropriate to consider reti noids 
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to be effectors that close cellular switches [12]. The nature of 
t he subsequent responses wou ld depend on the specific cell type 
being treated. 
Of more relevance to effects on cancer, retinoids are known 
to enhance cellular differentiation , even of malignant cell lines. 
For example, retinoids promote differentiation of embryona l 
ca rcinoma undifferentiated stem cell s into stable, non-neoplas-
tic differentiated cells. The HL-60 huma n promyelocytic leu-
kemia cell line is s imilarly induced to te rmina l benign differ-
entiation with retinoids, as the c-myc oncogene is being sup-
pressed. Retinoids also inhibit proliferation of malignant cell 
lines with accumulation of ce ll s in the G, phase of the cell 
cycle. Retinoids inhibi t chemical carcinogenesis in vivo in skin 
and other epithelia, such as breast, bladder, and lung. This 
inhibit ion can be augmented when retinoid treatment is com-
bined with other chemopreventive modalities. For example, 
t here is a synergistic effect in the inhibition of breast cancer in 
rats when retinoid t reatment is combined either with ovariec-
to my or with t reatment with bromocryptine, an inhibitor of 
prolactin secretion from t he pituitary. Retinoids suppress ma-
lignant tra nsformation in vitro whether t he carcinogenic stim-
ulus is a chemical carcinogen , ionizing radiation, or t he sarcoma 
growth factor of t he Moloney sarcoma virus. Retinoids inhibit 
tumor promotion and induction of orni thine decarboxylase by 
phorbol esters, but may also interfe re with tumor initiation , 
since they inhibit ca rcinogen-induced aryl hydrocarbon hy-
droxylase and inhibi t binding of ca rcinogen to DNA. 
In this issue of t he Journal , Levine describes a novel approach 
to the study of retinoid effects on melanoma. In t his in vivo 
model system, Cloudman 891 murine melanoma cells are in -
oculated into upper dermal bliste r cavities created by negative 
suction pressure in t he skin of DBA/2 mice. The resultant 
tumor nodules resemble cutaneous metastases of melanoma by 
virtue of their superficial dermal location. Topical applications 
of all-trans- retinoic acid at varying concentrations in DMSO, 
begun one day and continuing for 28 days after inoculation, 
prevents development of visible or palpable tumors and de-
creases incorporation of [' ''C]th iouraci l, a measure of mela noma 
growth, in a dose-dependent ma nner. Most of the retinoid-
t reated anima ls had moderate erythema at sites of application 
indicating that t he role of nonspecific inflammation as a pos-
sible cause of inhibition of tumor formation in t his system 
requires further study. 
Although it is more direct to study t he mechanisms of action 
of retinoids in ce ll cul ture, th is model system has potent ial 
utili ty in investigating t he in vivo factors , such as host immune 
status, t hat may modulate t he response to retinoid t herapy. 
Additionally, t his model for detecting a ntimelanoma activi ty 
cou ld be of value as a seconda ry efficacy screen for many of the 
more tha n 1500 retinoids t hat have been synthesized to date 
and have shown activity in preliminary in vitro screens. This 
system could be easily modified to a Llow study of t umors other 
than melanoma. This report also emphasizes the need for 
further investigation of t he effects of topical application of 
synthetic reti noids, which would include minimizing t he devel-
opment of systemic toxicity. 
The preclinical screening systems t hat have been most reg-
ularly employed to test t he effi cacy of newly synt hesized reti -
noids have been the mouse papilloma assay of Bollag and t he 
hamster tracheal organ cul ture system of Sporn. In t he for mer 
system mice are treated with the test retinoid after carcinogen 
exposure and observed for the appea rance of skin tumors. In 
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t he latter system retinoids are tested for t heir abili ty to reverse 
t he keratinization of t he squamous metap lasia seen in t he 
vitamin A-deficient hamster trac hea. Whereas t hese screens 
have been predictive of efficacy in benign and malignant epi-
thelial diseases, it is apparent t hat with t he expanding spectrum 
of reti noid-responsive diseases addit iona l screening systems are 
necessary. Exclusive reliance on one or two sc reens could result 
in t he loss of a valuable retinoid t hat could be effective in 
nonepithelial diseases, such as melanoma, myelodysp lastic syn-
dromes, and rheumatoid arthritis. 
Perhaps even more critical to t he future of retinoids is the 
placement of higher priority on screening new derivatives for 
acute and chronic toxicity t ha n for efficacy. It would be a major 
adva nce, indeed, if new retinoids were found to be equal in 
effi cacy to existing agents but markedly less toxic. In fact, some 
of t he more recently synthesized retinoids lac k the systemic 
toxicities t hat are so well known for isotretinoin and etretinate, 
such as alterations in liver function tests and serum lipids, 
teratogenicity, a nd bony toxicity. 
Thus, the future of the retinoids appears most promising, 
particularly with t he expanding spectrum of retinoid-respon-
sive diseases beyond t he familiar triad of acne, psoriasis, and 
cutaneous disorders of keratinization, and with t he continuing 
development of new synthetic compounds t hat may improve 
still further their efficacy, but more importantly, t heir tolera-
bility. 
Gary L. Pack, M.D. 
NCI, National Institutes of Health 
Bethesda, Maryland 
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